In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies

EUCAST Determination of olorofim (F901318) susceptibility of mould species, method validation and MICs

(2018) Karin Meinike Jørgensen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Orotomide Olorofim is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis

(2018) Nathan P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates

(2017) J. B. Buil et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans

(2017) Nathan P. Wiederhold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus

(2017) Clara E Negri et al.   JOURNAL OF INFECTIOUS DISEASES

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

(2016) Jason D. Oliver et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cryptic and Rare Aspergillus Species in Brazil: Prevalence in Clinical Samples and In Vitro Susceptibility to Triazoles

(2014) C. E. Negri et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Treatment of Infections by Cryptic Aspergillus Species

(2014) Wagner L. Nedel et al.   MYCOPATHOLOGIA

Antifungal Susceptibility Profile of Cryptic Species of Aspergillus

(2014) Ana Alastruey-Izquierdo et al.   MYCOPATHOLOGIA

Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study)

(2013) A. Alastruey-Izquierdo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agentsin vitro

(2010) Manuel Cuenca-Estrella et al.   Expert Review of Anti-Infective Therapy

Efflux-Mediated Antifungal Drug Resistance

(2009) R. D. Cannon et al.   CLINICAL MICROBIOLOGY REVIEWS

Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

(2009) J. W. Baddley et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network

(2009) S. A. Balajee et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Aspergillus Section Fumigati: Antifungal Susceptibility Patterns and Sequence-Based Identification

(2008) L. Alcazar-Fuoli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY